KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Asset Writedowns and Impairment (2016 - 2022)

Historic Asset Writedowns and Impairment for Travere Therapeutics (TVTX) over the last 6 years, with Q4 2022 value amounting to -$1.0 million.

  • Travere Therapeutics' Asset Writedowns and Impairment fell 1796.34% to -$1.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.0 million, marking a year-over-year increase of 10863.45%. This contributed to the annual value of $2.8 million for FY2024, which is 723.92% down from last year.
  • Latest data reveals that Travere Therapeutics reported Asset Writedowns and Impairment of -$1.0 million as of Q4 2022, which was down 1796.34% from $329000.0 recorded in Q3 2022.
  • Travere Therapeutics' 5-year Asset Writedowns and Impairment high stood at $25.5 million for Q1 2019, and its period low was -$1.0 million during Q4 2022.
  • In the last 4 years, Travere Therapeutics' Asset Writedowns and Impairment had a median value of $481000.0 in 2021 and averaged $2.9 million.
  • As far as peak fluctuations go, Travere Therapeutics' Asset Writedowns and Impairment tumbled by 13928.09% in 2021, and later skyrocketed by 9486.65% in 2022.
  • Travere Therapeutics' Asset Writedowns and Impairment (Quarter) stood at $25.5 million in 2019, then tumbled by 91.27% to $2.2 million in 2020, then crashed by 139.28% to -$874000.0 in 2021, then decreased by 17.96% to -$1.0 million in 2022.
  • Its last three reported values are -$1.0 million in Q4 2022, $329000.0 for Q3 2022, and $792000.0 during Q2 2022.